What is Trazodone? Understanding Its Uses, Side Effects, and More

Trazodone is a prescription medication classified as a serotonin antagonist and reuptake inhibitor (SARI). Primarily known for its antidepressant properties, it is widely used in the management and treatment of major depressive disorder. Beyond its FDA-approved indication, trazodone is also frequently prescribed off-label for insomnia and other conditions. This article delves into a comprehensive overview of trazodone, exploring its uses, mechanism of action, administration, potential side effects, and essential considerations for its use.

Indications for Trazodone

Trazodone has both FDA-approved and non-FDA-approved uses, making it a versatile medication in clinical practice.

FDA-Approved Indications

The primary FDA-approved indication for trazodone is the treatment of major depressive disorder (MDD). It can be used as monotherapy or as part of a combination therapy approach, alongside other medications or psychotherapeutic interventions, to manage depression effectively. The effectiveness of trazodone in alleviating symptoms of depression has been established through numerous clinical trials, leading to its approval for this condition.

Non-FDA-Approved Uses

Beyond depression, trazodone is commonly used off-label for a variety of conditions, primarily due to its sedative and anxiolytic properties. These non-FDA-approved uses include:

• Insomnia: Trazodone is frequently prescribed for insomnia, particularly when sleep disturbance is associated with depression or anxiety. Its sedative effects, even at lower doses, make it effective in promoting sleep onset and maintenance. Despite its widespread use for sleep, it is important to note that trazodone is not officially FDA-approved for sleep disorders due to the need for more robust clinical data to support this specific indication.
• Anxiety Disorders: Trazodone’s ability to modulate serotonin levels and block certain receptors contributes to its anxiolytic effects. It is sometimes used off-label to manage symptoms of anxiety disorders, although other antidepressants and anxiolytics are typically preferred as first-line treatments.
• Alzheimer’s Disease Agitation: In elderly patients with Alzheimer’s disease, trazodone has been used to manage agitation and behavioral disturbances. Its calming effects can help reduce aggression and improve overall behavior in these individuals.
• Substance Use Disorders: Trazodone has been explored as an adjunct medication in the management of substance use disorders. Its potential to improve sleep and mood may be beneficial during withdrawal and recovery phases.
• Bulimia Nervosa: Due to its influence on serotonin pathways, trazodone has been used in the treatment of bulimia nervosa, an eating disorder characterized by binge eating and compensatory behaviors.
• Fibromyalgia: Some studies suggest that trazodone may help alleviate pain and improve sleep quality in patients with fibromyalgia, a chronic musculoskeletal pain disorder.
• Post-traumatic Stress Disorder (PTSD) Nightmares: Trazodone has shown efficacy in reducing the frequency and intensity of nightmares associated with PTSD. Doses ranging from 50 to 200 mg have been studied for this purpose, with evidence suggesting improvement in sleep habits and nightmare reduction in PTSD patients. The American Academy of Sleep Medicine (AASM) suggests trazodone for treating PTSD-related nightmares. However, it is crucial to note that for PTSD itself, selective serotonin reuptake inhibitors (SSRIs) are generally preferred as first-line treatments due to reports of panic symptom exacerbation in some patients using trazodone.
• Obstructive Sleep Apnea (OSA): Research indicates that trazodone can improve apnea and hypopnea episodes in individuals with OSA. It may also lower the risk of respiratory instability by raising the respiratory threshold without worsening hypoxemic episodes.

Oral trazodone tablets in various dosages, highlighting the medication’s availability in solid form for oral administration.

How Trazodone Works: Mechanism of Action

Trazodone’s therapeutic effects stem from its complex mechanism of action, primarily involving modulation of serotonin activity in the brain. As a SARI, it exerts its effects through several pathways:

• Serotonin Reuptake Inhibition: Trazodone inhibits the serotonin transporter (SERT), which is responsible for reabsorbing serotonin from the synaptic cleft back into the presynaptic neuron. By blocking SERT, trazodone increases the availability of serotonin in the synapse, enhancing serotonergic neurotransmission. This is a common mechanism shared with other antidepressants like SSRIs, but trazodone’s effect on serotonin reuptake is generally considered weaker compared to SSRIs.
• 5-HT2 Receptor Antagonism: Trazodone is a potent antagonist of serotonin 5-HT2A and 5-HT2C receptors. Blocking these receptors is believed to contribute to its antidepressant, anxiolytic, and sleep-promoting effects. Antagonism of 5-HT2A receptors, in particular, is thought to be crucial for its efficacy in treating insomnia and minimizing sexual side effects often associated with SSRIs.
• Alpha-1-Adrenergic and Histamine H1 Receptor Blockade: Trazodone also blocks alpha-1-adrenergic and histamine H1 receptors. Alpha-1 blockade can contribute to orthostatic hypotension (a drop in blood pressure upon standing) and dizziness, while histamine H1 blockade contributes to sedation and drowsiness. These receptor actions are largely responsible for some of the common side effects of trazodone.

The combined action of serotonin reuptake inhibition and 5-HT2 receptor antagonism distinguishes trazodone from SSRIs and contributes to its unique therapeutic profile. Its ability to simultaneously inhibit SERT, 5-HT2A, and 5-HT2C receptors is thought to be advantageous in minimizing certain side effects like sexual dysfunction, insomnia, and anxiety, which are more prevalent with SSRIs and serotonin-norepinephrine reuptake inhibitors (SNRIs).

Furthermore, recent research has explored trazodone’s potential anti-inflammatory effects in the brain. Studies on human astrocytes have indicated that trazodone can reduce the release of inflammatory mediators and support neuronal health during inflammation, which is increasingly recognized as a factor in major depression. This suggests a broader neuroprotective role for trazodone beyond its direct neurotransmitter effects.

Pharmacokinetics of Trazodone

Understanding how the body processes trazodone is crucial for optimizing its use. Key pharmacokinetic properties include:

• Absorption: Trazodone is rapidly absorbed after oral administration, reaching peak plasma concentrations within approximately 1 hour. Its bioavailability is high, estimated to be around 100%, meaning almost the entire administered dose enters systemic circulation.
• Distribution: Trazodone is highly protein-bound, with 89% to 95% bound to plasma proteins. This high protein binding can influence drug interactions and distribution within the body.
• Metabolism: Trazodone is extensively metabolized in the liver, primarily by the cytochrome P450 enzyme CYP3A4. A major active metabolite is m-chlorophenylpiperazine (m-CPP), which also has pharmacological activity. CYP2D6 plays a minor role in its metabolism.
• Excretion: Trazodone is mainly excreted in the urine. The elimination half-life of trazodone ranges from 5 to 9 hours, which influences its dosing frequency and the time it takes to reach steady-state concentrations in the body.

A visual representation of serotonin neurotransmission, illustrating how trazodone impacts serotonin levels and receptor activity in the brain.

Administration and Dosage

Trazodone is available for oral administration and comes in immediate-release and extended-release formulations.

Dosage for Major Depressive Disorder

• Immediate-Release Formulation: The typical starting dose for treating major depressive disorder with immediate-release trazodone is 50 to 100 mg orally two or three times daily. Treatment usually begins with lower doses, such as 25 to 50 mg two or three times daily, and gradually increased in increments of 50 mg per day every 3 to 4 days. Outpatient dosages generally do not exceed 400 mg daily, while hospitalized patients may require up to 600 mg daily. It’s important to taper the dose gradually when discontinuing trazodone to minimize withdrawal symptoms.
• Extended-Release Formulation: Extended-release trazodone is designed for once-daily evening administration, typically starting at 75 to 150 mg before bedtime. This formulation aims to improve compliance and optimize antidepressant effects. The dose can be increased every three days, up to a maximum of 300 mg daily, and potentially higher (up to 600 mg) in hospitalized settings.

Dosage for Insomnia

For insomnia, lower doses of trazodone are typically used, usually ranging from 25 to 100 mg taken orally at bedtime. Studies have shown that doses of 50 to 100 mg are effective for nonorganic insomnia, particularly when associated with depressive disorders, with 100 mg often considered the most effective dose for sleep improvement.

Administration Guidelines

• Trazodone tablets are available in 50, 100, 150, and 300 mg strengths.
• It is often recommended to take trazodone after meals to reduce the likelihood of lightheadedness and postural hypotension.
• Abruptly stopping trazodone can lead to withdrawal symptoms such as nausea, dysphoria, agitation, and sensory disturbances. Gradual tapering is essential when discontinuing treatment.

Specific Patient Populations

• Hepatic and Renal Impairment: Caution is advised when using trazodone in patients with liver or kidney impairment, as its metabolism and excretion may be affected. Dose adjustments may be necessary, and close monitoring is recommended.
• Pregnancy: Pregnant patients with depression should be registered with the National Pregnancy Registry for Antidepressants to monitor outcomes. Current literature does not indicate an increased risk of miscarriage, congenital disabilities, or adverse fetal outcomes with trazodone use during pregnancy. However, the risk of untreated depression should be carefully weighed against the potential risks of medication.
• Breastfeeding: Trazodone is excreted in breast milk. While limited data suggests no significant adverse effects on breastfed infants, caution is advised. The maternal need for trazodone should be balanced against the benefits of breastfeeding.
• Pediatric Patients: Antidepressants, including trazodone, carry a boxed warning regarding an increased risk of suicidal thoughts and behaviors in pediatric and young adult patients. The safety and efficacy of trazodone in pediatric populations have not been definitively established.
• Older Patients: Older adults may be more sensitive to trazodone’s side effects. Lower starting doses, such as 100 mg per day, are recommended. Serotonergic antidepressants can increase the risk of hyponatremia (low sodium levels) in older adults, who are already at higher risk.

Adverse Effects and Risks

While trazodone is generally considered well-tolerated, it can cause a range of adverse effects. Common side effects include:

• Central Nervous System Effects: Drowsiness, sedation, dizziness, fatigue, and headache are frequent. Somnolence and hypotension are more likely during the initial week of treatment.
• Anticholinergic Effects: Dry mouth is a common anticholinergic side effect. However, compared to tricyclic antidepressants, trazodone is less likely to cause urinary retention and constipation.
• Cardiovascular Effects: Orthostatic hypotension and syncope (fainting) can occur, particularly due to alpha-1-adrenergic blockade. QT prolongation and Torsade de pointes (a dangerous heart rhythm abnormality) are rare but serious risks due to trazodone’s interaction with hERG potassium channels.
• Priapism: This is a rare but serious side effect involving a prolonged and painful erection. Men with conditions like sickle cell anemia, multiple myeloma, leukemia, or penile anatomical variations are at increased risk.
• Psychiatric Effects: Antidepressants, including trazodone, have a boxed warning about increased suicidal thoughts and behaviors, especially in younger individuals. Mania has been reported in some cases. Visual hallucinations are also a rare but reported side effect, typically resolving upon discontinuation.
• Bleeding Risk: Trazodone, like other antidepressants, may slightly increase the risk of bleeding, although this risk is generally lower than with some other antidepressants.

Boxed Warning

Trazodone, like all antidepressants, carries a boxed warning from the FDA regarding the increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults. Close monitoring for worsening depression, suicidal ideation, and unusual behavior changes is crucial when initiating or adjusting trazodone therapy in these age groups.

Drug-Drug Interactions

Trazodone can interact with various medications, potentially altering its effects or increasing the risk of side effects. Significant drug interactions include:

• CYP3A4 Inhibitors: Drugs that inhibit CYP3A4, such as clarithromycin, ketoconazole, and ritonavir, can increase trazodone levels, potentially leading to enhanced sedation and other side effects. Dose reduction of trazodone may be necessary when used with strong CYP3A4 inhibitors.
• Monoamine Oxidase Inhibitors (MAOIs): Concurrent use of trazodone with MAOIs (including linezolid and intravenous methylene blue) is contraindicated due to the risk of serotonin syndrome. A washout period of 14 days is required when switching between MAOIs and trazodone.
• Other Serotonergic Drugs: Combining trazodone with other serotonergic agents like SSRIs, SNRIs, tricyclic antidepressants (TCAs), triptans, and fentanyl can increase the risk of serotonin syndrome. Caution and careful monitoring are advised.
• Digoxin: Trazodone may increase digoxin levels. Therapeutic drug monitoring of digoxin is recommended when used concurrently with trazodone.
• Warfarin: Trazodone may interact with warfarin, potentially affecting INR levels. Monitoring PT/INR is advisable when these medications are used together.
• CNS Depressants: Combining trazodone with other central nervous system depressants like alcohol, benzodiazepines, and opioids can enhance sedation and respiratory depression. Caution should be exercised, and patients should be advised about potential additive effects.

Contraindications

Trazodone is contraindicated in certain situations:

• Monoamine Oxidase Inhibitors (MAOIs): As mentioned, concurrent use with MAOIs is contraindicated due to the risk of serotonin syndrome.
• Hypersensitivity: Known hypersensitivity to trazodone or any of its formulation components is a contraindication.

Caution is advised in patients with:

• Liver or Kidney Impairment: Due to potential alterations in metabolism and excretion.
• Cardiac Disease: Due to the risk of QT prolongation and orthostatic hypotension.
• History of Mania or Bipolar Disorder: Trazodone may induce mania in susceptible individuals.

Monitoring and Toxicity

Monitoring

Regular monitoring is important during trazodone therapy to ensure efficacy and safety. Key monitoring parameters include:

• Suicidal Ideation and Behavior: Especially at treatment initiation and dose changes, monitor for worsening depression and suicidal thoughts, particularly in younger patients.
• Serotonin Syndrome: Be vigilant for signs and symptoms of serotonin syndrome, such as mental status changes, neuromuscular abnormalities (tremor, clonus), and autonomic instability (hyperthermia, tachycardia).
• Liver Function Tests: Baseline and periodic liver function tests may be considered, although clinically significant liver toxicity is rare.
• Cardiovascular Monitoring: Monitor blood pressure for orthostatic hypotension, especially in older adults and those with pre-existing heart conditions. ECG monitoring may be considered in patients at risk for QT prolongation.
• Therapeutic Response: Regularly assess the patient’s response to trazodone therapy to determine if dose adjustments or alternative treatments are needed.
• Drug Interactions: Be aware of potential drug interactions and monitor for increased trazodone levels or adverse effects when used with interacting medications.

Toxicity and Overdose

Trazodone overdose can be serious and potentially life-threatening. Overdose symptoms may include:

• Central Nervous System Depression: Marked sedation, coma, respiratory depression.
• Cardiovascular Effects: Arrhythmias, hypotension.
• Priapism: Prolonged erection.
• Seizures and Cerebral Edema: Reported in severe overdose cases.
• Hyponatremia: Low sodium levels.

Treatment for trazodone overdose is primarily supportive and symptomatic. This may include:

• Supportive Care: Maintaining airway, breathing, and circulation.
• Activated Charcoal: May be considered if the overdose is recent and the patient is alert.
• Management of Hypotension: IV fluids, vasopressors if needed.
• Management of Seizures: Benzodiazepines.
• Management of Priapism: Urgent urological intervention, potentially including intracavernosal injection of phenylephrine.
• Monitoring and Correction of Hyponatremia:

In cases of suspected trazodone overdose, it is crucial to seek immediate medical attention and contact a poison control center for up-to-date management guidance.

Enhancing Healthcare Team Outcomes

Optimal patient care with trazodone requires a collaborative, interprofessional healthcare team approach. This team typically includes:

• Psychiatrists and Primary Care Physicians: Prescribe and manage trazodone therapy, diagnose conditions, and monitor overall patient health.
• Pharmacists: Dispense medications, check for drug interactions, provide patient education on medication use and side effects, and collaborate with prescribers to optimize medication management.
• Nurses: Educate patients on medication adherence, monitor for side effects and therapeutic response, and communicate patient concerns to the healthcare team.
• Clinical Psychologists and Therapists: Provide psychotherapy and behavioral interventions, especially for depression and insomnia, complementing medication treatment.

Effective communication and shared decision-making among all team members are essential to ensure patient safety, medication adherence, and optimal therapeutic outcomes. Regular team meetings, clear communication channels, and mutual respect among professionals contribute to enhanced healthcare team outcomes when utilizing trazodone in patient care.

Disclaimer: This article provides general information about trazodone and is intended for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider for any questions you may have regarding a medical condition or treatment.

References

1.Schwasinger-Schmidt TE, Macaluso M. Other Antidepressants. Handb Exp Pharmacol. 2019;250:325-355. [PubMed: 30194544]
2.McQuaid JR, Buelt A, Capaldi V, Fuller M, Issa F, Lang AE, Hoge C, Oslin DW, Sall J, Wiechers IR, Williams S. The Management of Major Depressive Disorder: Synopsis of the 2022 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Ann Intern Med. 2022 Oct;175(10):1440-1451. [PubMed: 36122380]
3.Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017 Feb 15;13(2):307-349. [PMC free article: PMC5263087] [PubMed: 27998379]
4.Khouzam HR. A review of trazodone use in psychiatric and medical conditions. Postgrad Med. 2017 Jan;129(1):140-148. [PubMed: 27744763]
5.Morgenthaler TI, Auerbach S, Casey KR, Kristo D, Maganti R, Ramar K, Zak R, Kartje R. Position Paper for the Treatment of Nightmare Disorder in Adults: An American Academy of Sleep Medicine Position Paper. J Clin Sleep Med. 2018 Jun 15;14(6):1041-1055. [PMC free article: PMC5991964] [PubMed: 29852917]
6.Smales ET, Edwards BA, Deyoung PN, McSharry DG, Wellman A, Velasquez A, Owens R, Orr JE, Malhotra A. Trazodone Effects on Obstructive Sleep Apnea and Non-REM Arousal Threshold. Ann Am Thorac Soc. 2015 May;12(5):758-64. [PMC free article: PMC4418332] [PubMed: 25719754]
7.Eckert DJ, Malhotra A, Wellman A, White DP. Trazodone increases the respiratory arousal threshold in patients with obstructive sleep apnea and a low arousal threshold. Sleep. 2014 Apr 01;37(4):811-9. [PMC free article: PMC4044741] [PubMed: 24899767]
8.Mandrioli R, Protti M, Mercolini L. New-Generation, Non-SSRI Antidepressants: Therapeutic Drug Monitoring and Pharmacological Interactions. Part 1: SNRIs, SMSs, SARIs. Curr Med Chem. 2018;25(7):772-792. [PubMed: 28707591]
9.Fagiolini A, Comandini A, Catena Dell’Osso M, Kasper S. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 2012 Dec;26(12):1033-49. [PMC free article: PMC3693429] [PubMed: 23192413]
10.Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mössner R, Müller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018 Jan;51(1-02):9-62. [PubMed: 28910830]
11.Odagaki Y, Toyoshima R, Yamauchi T. Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding. J Psychopharmacol. 2005 May;19(3):235-41. [PubMed: 15888508]
12.Wen B, Ma L, Rodrigues AD, Zhu M. Detection of novel reactive metabolites of trazodone: evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine. Drug Metab Dispos. 2008 May;36(5):841-50. [PubMed: 18238857]
13.Kale P, Agrawal YK. Pharmacokinetics of single oral dose trazodone: a randomized, two-period, cross-over trial in healthy, adult, human volunteers under fed condition. Front Pharmacol. 2015;6:224. [PMC free article: PMC4591485] [PubMed: 26483693]
14.Fiorentini A, Rovera C, Caldiroli A, Arici C, Prunas C, Di Pace C, Paletta S, Pozzoli SM, Buoli M, Altamura AC. Efficacy of oral trazodone slow release following intravenous administration in depressed patients: a naturalistic study. Riv Psichiatr. 2018 Sep-Oct;53(5):261-266. [PubMed: 30353201]
15.Menza MA. Withdrawal syndrome in a depressed patient treated with trazodone. Am J Psychiatry. 1986 Sep;143(9):1195. [PubMed: 3752308]
16.Nagler EV, Webster AC, Vanholder R, Zoccali C. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2012 Oct;27(10):3736-45. [PubMed: 22859791]
17.Einarson A, Bonari L, Voyer-Lavigne S, Addis A, Matsui D, Johnson Y, Koren G. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Can J Psychiatry. 2003 Mar;48(2):106-10. [PubMed: 12655908]
18.Saito J, Ishii M, Mito A, Yakuwa N, Kawasaki H, Tachibana Y, Suzuki T, Yamatani A, Sago H, Murashima A. Trazodone Levels in Maternal Serum, Cord Blood, Breast Milk, and Neonatal Serum. Breastfeed Med. 2021 Nov;16(11):922-925. [PMC free article: PMC8817729] [PubMed: 34348038]
19.Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Apr 18, 2022. Trazodone. [PubMed: 30000237]
20.Viramontes TS, Truong H, Linnebur SA. Antidepressant-Induced Hyponatremia in Older Adults. Consult Pharm. 2016 Mar;31(3):139-50. [PubMed: 26975593]
21.Haria M, Fitton A, McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging. 1994 Apr;4(4):331-55. [PubMed: 8019056]
22.Santos G, Moreira AM. Distressing Visual Hallucinations after Treatment with Trazodone. Case Rep Psychiatry. 2017;2017:6136914. [PMC free article: PMC5494093] [PubMed: 28702268]
23.Hu J, Lai J, Zheng H, Hu S, Xu Y. Fan the flame: trazodone-induced mania in a unipolar depressed patient with stable sertraline treatment. Neuropsychiatr Dis Treat. 2017;13:2251-2254. [PMC free article: PMC5576708] [PubMed: 28883733]
24.Bixby AL, VandenBerg A, Bostwick JR. Clinical Management of Bleeding Risk With Antidepressants. Ann Pharmacother. 2019 Feb;53(2):186-194. [PubMed: 30081645]
25.Kurian BT, Ray WA, Arbogast PG, Fuchs DC, Dudley JA, Cooper WO. Effect of regulatory warnings on antidepressant prescribing for children and adolescents. Arch Pediatr Adolesc Med. 2007 Jul;161(7):690-6. [PubMed: 17606833]
26.Amari DT, Juday T, Frech FH, Wang W, Wu Z, Atkins N, Wickwire EM. Falls, healthcare resources and costs in older adults with insomnia treated with zolpidem, trazodone, or benzodiazepines. BMC Geriatr. 2022 Jun 04;22(1):484. [PMC free article: PMC9166444] [PubMed: 35658904]
27.Farkas D, Volak LP, Harmatz JS, von Moltke LL, Court MH, Greenblatt DJ. Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem. Clin Pharmacol Ther. 2009 Jun;85(6):644-50. [PubMed: 19242403]
28.Otani K, Ishida M, Kaneko S, Mihara K, Ohkubo T, Osanai T, Sugawara K. Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine. Ther Drug Monit. 1996 Apr;18(2):164-7. [PubMed: 8721280]
29.Carvalhana S, Oliveira A, Ferreira P, Resende M, Perdigoto R, Barroso E. Acute Liver Failure due to Trazodone and Diazepam. GE Port J Gastroenterol. 2017 Jan;24(1):40-42. [PMC free article: PMC5553376] [PubMed: 28848778]
30.Jarema M, Dudek D, Landowski J, Heitzman J, Rabe-Jabłońska J, Rybakowski J. [Trazodon–the antidepressant: mechanism of action and its position in the treatment of depression]. Psychiatr Pol. 2011 Jul-Aug;45(4):611-25. [PubMed: 22232986]
31.Rauch PK, Jenike MA. Digoxin toxicity possibly precipitated by trazodone. Psychosomatics. 1984 Apr;25(4):334-5. [PubMed: 6718667]
32.Small NL, Giamonna KA. Interaction between warfarin and trazodone. Ann Pharmacother. 2000 Jun;34(6):734-6. [PubMed: 10860134]
33.Jurek L, Nourredine M, Megarbane B, d’Amato T, Dorey JM, Rolland B. [The serotonin syndrome: An updated literature review]. Rev Med Interne. 2019 Feb;40(2):98-104. [PubMed: 30243558]
34.Avila JD. Fatal Cerebral Edema, Seizures, and Hyponatremia After Trazodone Overdose. Clin Neuropharmacol. 2017 Sep/Oct;40(5):221-223. [PubMed: 28816830]
35.Wen CC, Munarriz R, McAuley I, Goldstein I, Traish A, Kim N. Management of ischemic priapism with high-dose intracavernosal phenylephrine: from bench to bedside. J Sex Med. 2006 Sep;3(5):918-922. [PubMed: 16942536]
36.Nichol JR, Sundjaja JH, Nelson G. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Apr 30, 2024. Medical History. [PubMed: 30484996]